Tezepelumab is under clinical development by Amgen and currently in Phase III for Eosinophilic Esophagitis. According to GlobalData, Phase III drugs for Eosinophilic Esophagitis have a 40% phase ...

The CEO discussed the success of Dupixent and the remarkable achievement of over $13 billion in global sales in 2024, highlighting its commercial advantage and setting a milestone for Sanofi.

Among other topics, Hudson discussed the success of Dupixent (dupilumab), highlighting that it has reached over $13bn in global sales, which affirms its commercial advantage and sets a milestone ...

The use of Sanofi’s Dupixent in atopic dermatitis has set a high benchmark for competitors within the space. Credit: marishkaSm via Shutterstock. Sanofi’s participation at the JP Morgan 43rd Annual ...

Sanofi’s chief executive Paul Hudson discussed the success of Dupixent (dupilumab)and the remarkable achievement of over $13 billion in global sales in 2024, highlighting its commercial advantage and ...

Furthermore, the successful launch of Dupixent for chronic obstructive pulmonary disease (COPD) has garnered significant coverage from top commercial and Medicare payers, indicating strong market ...

Dupixent (dupilumab) is a brand-name injection that’s prescribed for treating asthma. This article covers topics such as side effects, dosage, and how Dupixent works. Dupixent is available as a ...

The following is a summary of “Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled ...

Dupixent pen and syringe are two different devices used to inject the drug. They’re prefilled with the same amount of Dupixent and share other features, but certain factors make the pen easier ...

Tezepelumab may address type 2 low asthma ... Omalizumab (Xolair; Genentech, Novartis), dupilumab (Dupixent; Regeneron, Sanofi) and mepolizumab (Nucala, GSK) have varying effectiveness among ...

aUnit of Respiratory Medicine, Department of Experimental Medicine, University of Rome ‘Tor Vergata’, 00131 Rome, Italy bUnit of Pharmacology, Department of Experimental Medicine, University of ...

Tezepelumab is under clinical development by Amgen and currently in Phase II for Granulomatosis with Polyangiitis (Wegener’s Granulomatosis). According to GlobalData, Phase II drugs for Granulomatosis ...